Board Committee Changes

27 January 2022

Convatec Group Plc ("Convatec" or "the Company") is pleased to announce that Professor Constantin Coussios, a Non-Executive Director of the Company, has today been appointed as a member of the Company's Remuneration Committee and Nomination Committee.

This announcement is made in accordance with Listing Rule 9.6.11R (3).

Enquiries:

Analysts and Investors

Kate Postans, Vice President, Investor Relations +44(0)7826 447 807

ir@convatec.com

Media

Buchanan: Chris Lane +44(0)207 466 5000

Convatec Group Plc's LEI code is 213800LS272L4FIDOH92

About Convatec Group Plc
Convatec is a global medical products and technologies company focused on therapies for the management of chronic conditions, with leading market positions in advanced wound care, ostomy care, continence and critical care, and infusion care. Our vision, which encompasses our purpose, is: Pioneering trusted medical solutions to improve the lives we touch. Our products provide a range of clinical and economic benefits including infection prevention, protection of at-risk skin, improved patient outcomes and reduced total cost of care. To learn more about Convatec, please visit www.convatecgroup.com

Press Release

See all

17-Nov-22

Corporate

Capital Markets Event

10-Nov-22

Corporate

Financial Performance

Convatec Group Plc Trading update for the ten months ended 31 October 2022

04-Aug-22

Corporate

Financial Performance

Interim Results for the six months ended 30 June 2022

18-May-22

Corporate

New survey finds 87% of patients with long-term health conditions face stigma; nurses feel they lack time and resources to provide adequate support

Convatec makes 'forever caring' promise to patients and healthcare providers

12-May-22

Corporate

Financial Performance

AGM trading update for the four months ended 30 April 2022

09-May-22

Corporate

Continence Care

Convatec invests in BlueWind Medical to fund development of innovative neuromodulation technology

14-Mar-22

Corporate

Advanced Wound Care

Convatec Group completes acquisition of Triad Life Sciences Inc as it enters attractive wound biologics segment1

08-Mar-22

Corporate

Financial Performance

Annual Results for the twelve months ended 31 December 2021

28-Feb-22

Corporate

Our People

Non-Executive Directors - Appointment and Resignation

28-Jan-22

Corporate

Advanced Wound Care

Entry into the attractive wound biologics segment through the acquisition of Triad Life Sciences Inc

27-Jan-22

Corporate

Our People

Board Committee Changes